Brokerages Set Lucid Diagnostics Inc. (NASDAQ:LUCD) Price Target at $3.55

Lucid Diagnostics Inc. (NASDAQ:LUCD) has received a consensus rating of “Buy” from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $3.55.

Several analysts have commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $2.00 price objective on shares of Lucid Diagnostics in a report on Thursday, May 15th. Wall Street Zen lowered Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Ascendiant Capital Markets raised their price objective on Lucid Diagnostics from $7.50 to $7.75 and gave the company a “buy” rating in a report on Friday, June 6th. BTIG Research set a $2.00 price objective on Lucid Diagnostics in a report on Tuesday, March 25th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a report on Wednesday, May 14th.

Institutional Trading of Lucid Diagnostics

Institutional investors have recently made changes to their positions in the company. Berkshire Asset Management LLC PA purchased a new position in Lucid Diagnostics during the first quarter worth approximately $30,000. Northwestern Mutual Wealth Management Co. purchased a new position in Lucid Diagnostics during the first quarter worth approximately $37,000. Cubist Systematic Strategies LLC purchased a new position in Lucid Diagnostics during the first quarter worth approximately $39,000. Parallel Advisors LLC purchased a new position in Lucid Diagnostics during the second quarter worth approximately $46,000. Finally, LPL Financial LLC lifted its position in Lucid Diagnostics by 29.1% during the fourth quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock worth $44,000 after buying an additional 12,035 shares in the last quarter. 74.01% of the stock is owned by institutional investors and hedge funds.

Lucid Diagnostics Stock Down 3.4%

Lucid Diagnostics stock opened at $1.14 on Friday. Lucid Diagnostics has a 52 week low of $0.72 and a 52 week high of $1.80. The business’s 50-day moving average price is $1.25 and its 200 day moving average price is $1.23. The firm has a market cap of $123.34 million, a price-to-earnings ratio of -0.85 and a beta of 1.23.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.